Immunic Inc is progressing its lead drug vidofludimus calcium through Phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026. Positive results could lead to a US regulatory submission in mid-2027 and a decision in 2028. The company is also preparing a Phase 3 trial for progressive MS later this year, following promising Phase 2 data. Immunic has strengthened its leadership team and reported increased expenses and a net loss in Q2 2026, but holds $155.1 million in cash to support operations into late 2027.
Rockwell Automation has launched an integration between its Plex Quality Management System (QMS) and FactoryTalk Analytics VisionAI, enabling AI-driven visual inspection within manufacturing workflows. This integration enhances quality control by imp...
Paramount's board has approved a plan to move the studio out of California if Attorney General Rob Bonta does not agree to settlement talks by October 1 amid an antitrust lawsuit over its $110 billion Warner Bros. acquisition. CEO David Ellison warne...
Keel Infrastructure has shut down all its U.S. bitcoin mining operations as it transitions to AI and high-performance computing, citing higher returns from AI infrastructure. The move caused Q2 revenue to drop 50% to $30.4 million and a net loss of $...
American Water, the largest regulated water utility in the U.S., was recognized by Forbes and Statista as one of America's Best Employers for Women in 2026 based on an independent employee survey. The company emphasizes diversity, inclusion, and care...
Thunder Gold Corp. announced its best-ever diamond drill results at the Tower Mountain property in Ontario, with a 661.5-meter mineralized interval averaging 0.554 g/t gold and a 24-meter continuous interval averaging 1.815 g/t gold. The drilling ext...
